Table 1.
Baseline characteristics of the study population receiving dietary supplementation of selenium and coenzyme Q10 combined or placebo during four years.
| Active Treatment Group n = 106 |
Placebo Group n = 107 |
p-Value | |
|---|---|---|---|
| Age years, mean (SD) | 77.0 (3.7) | 77.0 (3.3) | 0.36 |
| Gender, Males/Females | 43/64 | 46/61 | |
| History | |||
| Diabetes, n (%) | 25 (23.6) | 21 (19.6) | 0.51 |
| Smoking, n (%) | 9 (8.5) | 12 (11.2) | 0.50 |
| Hypertension, n (%) | 75 (70.8) | 75 (70.1) | 0.92 |
| IHD, n (%) | 18 (17.0) | 22 (20.6) | 0.50 |
| NYHA class I, n (%) | 54 (50.9) | 57 (53.3) | 0.73 |
| NYHA class II, n (%) | 33 (31.1) | 26 (24.3) | 0.27 |
| NYHA class III, n (%) | 19 (17.9) | 23 (21.5) | 0.51 |
| NYHA class IV, n (%) | 0 | 0 | |
| Medications | |||
| ACEI/ARB, n (%) | 18 (17.0) | 20 (18.7) | 0.74 |
| Beta blockers, n (%) | 32 (30.2) | 24 (22.4) | 0.20 |
| Diuretics, n (%) | 29 (27.4) | 32 (29.9) | 0.68 |
| Statins, n (%) | 20 (18.9) | 20 (18.7) | 0.97 |
| Examinations | |||
| EF < 40%, n (%) | 2 (1.9) | 7 (6.5) | 0.20 |
| s-selenium pre-intervention µg/L, mean (SD) | 67.6 (14.8) | 66.3 (15.8) | 0.98 |
Note: ACEI: ACE- inhibitors; ARB: Angiotension receptor blockers; EF: Ejection fraction; IHD: Ischemic heart disease; NYHA: New York Heart Association functional class; SD: Standard Deviation. Note: Values are means ± SDs or frequency (percent). Note: Student’s unpaired two-sided t-test was used for continuous variables and the chi-square test was used for analysis of one discrete variable.